Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Monitoring chronic myelogenous leukemia in the age of tyrosine kinase inhibitors.

Journal of the National Comprehensive Cancer Network : JNCCN - 1 May 2007

Radich Jerald P, Oehler Vivian

Abstract excerpt

Tyrosine kinase inhibitors (TKIs) are now standard up-front therapy for chronic myeloid leukemia (CML). Patients with newly diagnosed chronic-phase CML treated with the TKI imatinib mesylate typically experience a complete cytogenetic remission. Outcomes for patients with advanced-phase disease are distinctly worse. Unfortunately, a small proportion of chronic-phase patients experience relapse during this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Chromosome Aberrations
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Treatment Outcome

Source

Identifiers

PMID: 17509253
DOI: 10.6004/jnccn.2007.0044

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Monitoring chronic myelogenous leukemia in the age of tyrosine kinase inhibitors.PMID 17509253Read ↗

Monitoring patients with chronic myeloid leukemia receiving Abl tyrosine kinase inhibitor therapy.Semantic proximity Read ↗

Molecular monitoring in patients with chronic myelogenous leukemia.Semantic proximity Read ↗

Molecular monitoring of chronic myeloid leukemia: present and future.Semantic proximity Read ↗

Molecular monitoring in CML: how deep? How often? How should it influence therapy?Semantic proximity Read ↗

Monitoring response to tyrosine kinase inhibitor therapy, mutational analysis, and new treatment options in chronic myelogenous leukemia.Semantic proximity Read ↗

Monitoring disease response to tyrosine kinase inhibitor therapy in CML.Semantic proximity Read ↗

Chronic myeloid leukemia: molecular monitoring in clinical practice.Semantic proximity Read ↗

Molecular monitoring in chronic myeloid leukemiaSemantic proximity Read ↗

Best Practices in Chronic Myeloid Leukemia Monitoring and Management.Semantic proximity Read ↗

Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.Semantic proximity Read ↗

Present and future of molecular monitoring in chronic myeloid leukaemia.Semantic proximity Read ↗

Monitoring Chronic Myeloid Leukemia: How Molecular Tools May Drive Therapeutic ApproachesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.